This NDC is on FDA's drug shortage list (posted Apr 2, 2020)
Reported reason: Demand increase for the drug
Product Information
MIDAZOLAM HCL 10 MG/2 ML VIAL is a generic product labeled by Hospira Inc., priced at $0.5652 per ML under NDC 00409230802. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jul 22, 2002. Its Orange Book therapeutic-equivalence code is AP.
Strength
5 mg/mL
Manufacturer
Hospira Inc.NDC
00409230802
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
MIDAZOLAM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075857FDA Approved
7/22/2002
TE Code
AP
On Market Since
6/14/2005
Pharmacological Classes
Price Statistics
The NADAC for MIDAZOLAM HCL 10 MG/2 ML VIAL has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5652 per ML |
|---|---|
| All-time high | $0.6092 (Nov 13, 2024) |
| All-time low | $0.5545 (Apr 22, 2026) |
| 52-week high | $0.6031 |
| 52-week low | $0.5545 |
| Median price | $0.6016 |
| Average price | $0.5885 |
| Largest weekly change | +3.5% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 32% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MIDAZOLAM HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MIDAZOLAM HCL 10 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for MIDAZOLAM HCL 10 MG/2 ML VIAL, manufactured by Hospira Inc., is $0.5652 per ML (NDC 00409230802), effective Sep 30, 2026.
How has the price of MIDAZOLAM HCL 10 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for MIDAZOLAM HCL 10 MG/2 ML VIAL has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for MIDAZOLAM HCL 10 MG/2 ML VIAL?
Since Apr 17, 2024, the NADAC for MIDAZOLAM HCL 10 MG/2 ML VIAL has ranged from a low of $0.5545 (Apr 22, 2026) to a high of $0.6092 (Nov 13, 2024), with a median of $0.6016 per ML.
Are there cheaper alternatives to MIDAZOLAM HCL 10 MG/2 ML VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MIDAZOLAM HCL 50 MG/10 ML VIAL, is $0.3817 per ML — about 32% below MIDAZOLAM HCL 10 MG/2 ML VIAL.
Who manufactures MIDAZOLAM HCL 10 MG/2 ML VIAL?
MIDAZOLAM HCL 10 MG/2 ML VIAL (NDC 00409230802) is labeled by Hospira Inc., and CMS classifies it as a generic product.
Is MIDAZOLAM HCL 10 MG/2 ML VIAL in shortage?
Yes — NDC 00409230802 is currently listed in FDA's drug shortage database (posted Apr 2, 2020). Reported reason: Demand increase for the drug.